Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
The discovery could provide opportunities to target resistance driven by aberrantly spliced forms of BRAF V600E.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.
First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced MelanomaOctober 22, 2018
First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.
T-VEC elicited substantially higher ORR in a real-world population compared with the rate that was seen in the drug maker's phase 3 trial.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLCOctober 17, 2018
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Treatment with ipilimumab plus nivolumab in the neoadjuvant setting resulted in high patient response rates — but it was linked to high toxicity, as well.
Future studies on checkpoint inhibition in melanoma must evaluate ways of reducing toxicity.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Updated results show prolonged responses to brain metastases.
Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.
A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Although checkpoint inhibitors are active against melanoma-linked brain metastases, researchers are interested in exploring combination approaches.
A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.
Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.
Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.
The use of tanning beds and/or booths and their availability in gyms may increase the frequency of indoor tanning for physically active adults, a combination that further exacerbates their risk for melanoma.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?